Although metformin remains the pharmacotherapy of the first choice for T2DM patients without any additional risk, according to the American Diabetes Association, GLP-1 analogs should be chosen as a first-line treatment, together with Sodium-glucose Cotransporters-2 (SGLT-2s), in case of T2DM and established chronic kidney disease (CKD), atherosclerotic cardiovascular disease (ASCVD), or indicators of high ASCVD risk independent of HbA1C levels [19]. The gene discussed is GLP1R; the disease is atherosclerosis.